Thrombosis in Cancer Patients Treated with Hematopoietic Growth Factors - A Meta-Analysis

T Barbul; G Finazzi; A Grassi; R Marchioli

doi:10.1055/s-0038-1650276

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1996; 75(02): 368-371
DOI: 10.1055/s-0038-1650276

Scientific and Standardization Committee Communication

Schattauer GmbH Stuttgart

Thrombosis in Cancer Patients Treated with Hematopoietic Growth Factors - A Meta-Analysis

On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH

Authors

T Barbul

¹The Divisione di Ematologia Ospedali Riuniti, Bergamo, Italy
G Finazzi

¹The Divisione di Ematologia Ospedali Riuniti, Bergamo, Italy
A Grassi

¹The Divisione di Ematologia Ospedali Riuniti, Bergamo, Italy
R Marchioli

²Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy

Abstract

PDF Download

Summary

Hematopoietic colony-stimulating factors (CSFs) are largely used in patients with cancer undergoing cytotoxic treatment to accelerate neutrophil recovery and decrease the incidence of febrile neutropenia. Clinical practice guidelines for their use have been recently established (1), taking into account clinical benefit, but also cost and toxicity. Vascular occlusions have been recently reported among the severe reactions associated with the use of CSFs, in anedoctal case reports (2, 3), consecutive case series (4) and randomized clinical trial (5, 6). However, the role of CSFs in the pathogenesis of thrombotic complications is difficult to ascertain, because pertinent data are scanty and widely distributed over a number of heterogenous investigations. We report here a systematic review of relevant articles, with the aims to estimate the prevalence of thrombosis associated with the use of CSFs and to assess if this rate is significantly higher than that observed in cancer patients not receiving CSFs.

PDF (263 kb)

References

References
1 American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994 12. 2471-2508
2 Lindemann A, Rumberger B. Vascular complications in patients treated with granulocyte colony stimulating factor (G-CSF). Eur J Cancer 1993; 16: 2338-2339
3 Conti JA, Scher HI. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. Cancer 1992; 70: 2699-2702
4 Stephens LC, Haire WD, Schmit-Pokomy K, Kessinger A, Kotulak G. Granulocyte macrophage colony stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone Marrow Transplantation 1993; 11: 51-54
5 Biesma B, deVries EGE, Willemse PHB, Sluiter WJ, Postmus PE, Limburg PC, Stem AC, Vellenga E. Efficacy and tolerability of recombinant human granulocyte-macrophage colony stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 1990; 26: 932-936
6 Gorin NC, Coiffier B, Hayat M, Fouillard L, Kuentz M, Flesch M, Colom-bat P, Boivin P, Slavin S, Lemarie JC, Eugene-Jolchine I, Philip T. Facteur de croissance hematopoietique (GM-CSF) apres autogreffe de moelle osseuse. La Presse Medicale 1993; 22: 109-120
7 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748
8 Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 1994; 12: 560-568
9 Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco Bianchi L, Fiorentino MV. Granulocyte-macrophage colony stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics. Cancer 1993; 72: 697-706
10 Bukowski RM, Murty S, McLain D, Finke J, Andresen S, Tubbs R, Bauer L, Gibson V, Budd GT, Thomassen MJ. Phase I trial of recombinant granulocyte-macrophage colony stimulating factor in patients with lung cancer: clinical and immunologic effects. J Immunother 1993; 13: 267-274
11 Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994; 12: 77-82
12 Gridelli C, De Placido S, Pepe R, Incoronato P, Airoma G, Rossi A, Palaz-zolo G, Bianco AR. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. Eur J Cancer 1993; 29A (12) 1729-1731
13 Eguchi K, Etou H, Miyachi S, Morinari H, Nakada K, Noda K, Ohkuni Y, Watanabe K, Yamada Y, Ohe Y, Tamura T, Sasaki Y, Shonkai T, Saijo N. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. Eur J Cancer 1994; 30A (02) 188-194
14 Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakawaga K, Hirashima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N, Takada M. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 90-96
15 Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlinok G, Mueller P, Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp JH, Thiel E, Huber C, Peschl C, Spann W, Emmerich B, Schadek C, Westerhausen M, Pees HW, Radtke H, Engert A, Terhardt E, Schick H, Binder T, Fuchs R, Hasford J, Brandmeier R, Stem AC, Jones TC, Ehrlich HJ, Stein H, Parwaresch M, Tiemann M, Lennert K. Randomized, doubleblind, placebo-controlled phase III study of recombinant human granulocyte-macrophage colony stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas. Blood 1993; 82: 2329-2339
16 Schriber JR, Negrin RS, Chao NJ, Long GD, Homing SJ, Blume KG. The efficacy of granulocyte colony stimulating factor following autologous bone marrow transplantation for non-Hodgkin’s lymphoma with monoclonal antibody purged bone marrow. Leukemia 1993; 7: 1491-1495
17 Bolwell BJ, Fishleder A, Andresen SW, Lichtin AE, Koo A, Yanssens T, Burwell R, Baucco P, Green R. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affcting bone marrow engrafment. Bone Marrow Transplant 1993; 12: 609-614
18 Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, Blume KG. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83: 2823-2828
19 Ardizzoni A, Venturini M, Sertoli MR, Giannessi PG, Brema F, Danova M, Testore F, Mariani GL, Pennucci MC, Queirolo P, Silvestro S, Bruzzi P, Lionetto R, Latini F, Rosso R. Granulocyte-macrophage colony stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. BrJ Cancer 1994; 69: 385-391
20 Kritz A, Crown JP, Motzer RJ, Reich LM, Heller G, Moore MP, Hamilton N, Yao TJ, Heelan RT, Schneider JG, Moore MAS, McCormick B, Gilew-ski TA, O’Reilly RJ, Gulati SC, Norton L. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony stimulating factor. A randomized trial. Cancer 1993; 71: 2515-2521
21 Gulati SC, Bennett CL. Granulocyte-macrophage colony stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Int Med 1992; 116: 177-182
22 De Vries EGE, Biesma D, Willemse PHB, Mulder NH, Stem AC, Aalders JG, Vellenga E. A double-blind placebo-controlled study with granulocyte-macrophage colony stimulating factor during chemotherapy for ovarian carcinoma. Cancer Research 1991; 51: 116-122
23 Neumunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner D, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM. Recombinant human granulocyte-macrophage colony stimulating factor after bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-1778
24 De Witte T, Vreugdenhil G, Schattanberg A. Prolonged administration of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) after T-cell depleted allogeneic bone marrow transplantation. Transplant Proceed 1993; 25: 57-60
25 De Witte T, Gratwohl A, Van der Lely N, Bacigalupo A, Stem AC, Speck B, Schattenberg A, Nissen C, Gluckman E, Fibbe WE. Recombinant human granulocyte-macrophage colony stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T cell-depleted bone marrow transplantation. Blood 1992; 79: 1359-1365
26 Advani R, Chao NJ, Homing SJ, Blume KG, Ahn DK, Lambom KR, Fleming NC, Bonnem EM, Greenberg PL. Granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Int Med 1992; 116: 183-189
27 Gore SD, Donnenberg AD, Zehnbauer BA, Weng LJ, Burke PJ. Granulocyte-macrophage colony stimulating factor (GM-CSF) given concurrently with induction therapy for acute myelogenous leukemia (AML) augments the syndrome of T-lymphocyte recovery. Leukemia 1994; 8: 409-419
28 Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T, Gordon-Smith E, Milliken S, Tiley C. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417-1420
29 Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13: 233-238
30 Shimoda K, Okamura S, Inaba S, Okamura T, Ohga S, Ueda K, Niho Y. Granulocyte colony-stimulating factor and platelet aggregation. Lancet 1993; 341: 633
31 Rivera J, Zuazu I, Sanchez MJ, Rosillo MC, Arribas F, Heras I, Moraleda JM, Vicente V. Effect of G-CSF on the haemostatic system. Thromb Haemostas 1994; 71: 804-805
32 Gasson JC, Weisbart RH, Kaufman SE, Clark SC, Golde DW. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science 1984; 226: 1339-1342
33 Amaout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins as mature granulocyte. J Clin Invest 1986; 78: 597-601